| Literature DB >> 32850742 |
Dake Hao1,2, Ruiwu Liu3, Kewa Gao1,2, Chuanchao He1, Siqi He1,2, Cunyi Zhao4, Gang Sun4, Diana L Farmer1,2, Alyssa Panitch1,5, Kit S Lam3, Aijun Wang1,2,5.
Abstract
Endothelial cell (EC) transplantation via injectable collagen hydrogel has received much attention as a potential treatment for various vascular diseases. However, the therapeutic effect of transplanted ECs is limited by their poor viability, which partially occurs as a result of cellular apoptosis triggered by the insufficient cell-extracellular matrix (ECM) engagement. Integrin binding to the ECM is crucial for cell anchorage to the surrounding matrix, cell spreading and migration, and further activation of intracellular signaling pathways. Although collagen contains several different types of integrin binding sites, it still lacks sufficient specific binding sites for ECs. Previously, using one-bead one-compound (OBOC) combinatorial technology, we identified LXW7, an integrin αvβ3 ligand, which possessed a strong binding affinity to and enhanced functionality of ECs. In this study, to improve the EC-matrix interaction, we developed an approach to molecularly conjugate LXW7 to the collagen backbone, via a collagen binding peptide SILY, in order to increase EC specific integrin binding sites on the collagen hydrogel. Results showed that in the in vitro 2-dimensional (2D) culture model, the LXW7-treated collagen surface significantly improved EC attachment and survival and decreased caspase 3 activity in an ischemic-mimicking environment. In the in vitro 3-dimensional (3D) culture model, LXW7-modified collagen hydrogel significantly improved EC spreading, proliferation, and survival. In a mouse subcutaneous implantation model, LXW7-modified collagen hydrogel improved the engraftment of transplanted ECs and supported ECs to form vascular network structures. Therefore, LXW7-functionalized collagen hydrogel has shown promising potential to improve vascularization in tissue regeneration and may be used as a novel tool for EC delivery and the treatment of vascular diseases.Entities:
Keywords: cell engraftment; collagen hydrogel; endothelial cell; integrin-based ligand; tissue regeneration
Year: 2020 PMID: 32850742 PMCID: PMC7403189 DOI: 10.3389/fbioe.2020.00890
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
FIGURE 1Chemical synthesis of (SILY)2-LXW7 or SILY-(LXW7)2.
FIGURE 2Attachment of ECFCs on LXW7-treated collagen surface. (A) Images of ECFC attachment on untreated collagen surface (a), (SILY)2-LXW7 treated collagen surface (b) and SILY-(LXW7)2 treated collagen surface (c). Scale bar = 100 μm. (B) Quantification of the number of ECFCs attached on the different treated surfaces. Data were expressed as mean ± standard deviation: ∗∗p < 0.01 (n = 5).
FIGURE 3Apoptosis and survival of ECFCs on LXW7-treated collagen surface. (A) Quantification of caspase 3 expression of ECFCs cultured on different treated surfaces under ischemic-mimicking hypoxic environment. (B) Quantification of survival of ECFCs cultured on the different treated surfaces under ischemic-mimicking hypoxic environment. Data were expressed as mean ± standard deviation: ∗p < 0.05 (n = 5).
FIGURE 4HPLC evaluation of LXW7 conjugation on collagen hydrogel. The elution of unbound free SILY-(LXW7)2 into the incubating PBS was quantified using HPLC. The peak of SILY-(LXW7)2 was not shown until the amount of SILY-(LXW7)2 used to modify collagen hydrogel was up to 5 nmol/mg, and the peaks increased as the amount of SILY-(LXW7)2 increased.
FIGURE 5ECFC spreading and spouting in LXW7-modified collagen hydrogel. (A) Images of ECFC morphology in untreated collagen hydrogel (a) and LXW7-modified collagen hydrogel (b) after 1 day culture and ECFC morphology in untreated collagen hydrogel (c) and LXW7-modified collagen hydrogel (d) after 3 day culture. Scale bar = 100 nm. (B) Quantification of the cell area of ECFCs cultured in collagen hydrogel with different modification. (C) Quantification of the number of sprouts of ECFCs cultured in collagen hydrogel with different modification. Data were expressed as mean ± standard deviation: ∗p < 0.05 (n = 5).
FIGURE 6Network formation of ECFCs in LXW7-modified collagen hydrogel was blocked by an anti-αvβ3 integrin blocking antibody. (A) Network formation of ECFCs cultured in untreated collagen hydrogel (a), network formation of ECFCs pretreated with an anti-αvβ3 integrin blocking antibody cultured in LXW7-modified collagen hydrogel (b) and network formation of ECFCs cultured in LXW7-modified collagen hydrogel (c). Scale bar = 200 μm. (B) Quantification of the numbers of vessel network. (C) Quantification of the total vessel network length. Data were expressed as mean ± standard deviation: ∗p < 0.05 (n = 5).
FIGURE 7ECFC proliferation and survival in LXW7-modified collagen hydrogel. (A) Quantification of cell metabolic activity and proliferation of ECFCs cultured in collagen hydrogel with or without LXW7 modification for 5 days. (B) Quantification of survival of ECFCs cultured in collagen hydrogel with or without LXW7 modification under ischemic-mimicking hypoxic environment for 5 days. Data were expressed as mean ± standard deviation: ∗p < 0.05, ∗∗p < 0.01 (n = 5).
FIGURE 8ECFC engraftment in LXW7-modified collagen hydrogel after implantation. (A) IVIS imaging of implanted ECFC engraftment in untreated collagen hydrogel (right side on animal) and LXW7-modified collagen hydrogel (left side on animal) at different time points. The belly of animal was facing you in the image. (B) Quantification of the luciferase intensity of the engrafted ECFCs in collagen hydrogel with or without LXW7 modification at different time points. Data were expressed as mean ± standard deviation: ∗p < 0.05 (n = 4).
FIGURE 9Immunohistological analysis of ECFC survival and engraftment after in vivo transplantation. (A) GFP staining of implanted ECFCs in untreated collagen hydrogel (a) and LXW7-modified collagen hydrogel (b) at week 10. (B) High magnification imaging of the boxed area of (A).